Nicolaj Nielsen
Denmark, Copenhagen
CFO, Inprother Aps


InProTher is an immunotherapy company dedicated to developing the world’s first adaptive immune therapy capable of targeting immunosuppressive genes of ancient retroviruses that normally are dormant in the human genome. The retroviral genes are reactivated in cancer and essential for tumor development. InProTher’s proprietary combination of novel technologies is designed to break tolerance to this unique antigen family, thus providing broad anti-cancer efficacy.

Hosted By:
Processing. Please wait.